|
|
|
| Analysis of Prognostic Risk Factors in Patients Infected by Acinetobacter Baumannii in Hospital's Intensive Care Unit |
| LIU Hongshuan, CAI Yangping, ZHANG Qing, et al |
| Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, 101121, China |
|
|
|
|
Abstract Objective:To investigate clinical status and Antibiotics for drug-resistance of Acinetobacter baumannii (AB) infection in ICU. Methods: The clinical data of 158 patients with Acinetobacter baumannii infection hospitalized in the East Intensive Care Unit (ICU) of Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine from January 2014 to December 2017 were retrospectively analyzed, including annual isolation rate, strain source, prognosis and drug resistance. Results: The infection rate of AB was 12.2%, the mortality was 19.6%, and the isolation rate of strains decreased year by year. The source of the strain was mainly respiratory sputum, which was the main cause of pulmonary infection in ICU patients, especially ventilator-associated pneumonia. The antibiotics drug-resistant of AB accounted for 65.2%, and the resistance rate of various broad-spectrum antibiotics showed an increasing trend annual. The death group infected by AB was older、shorter remained in ICU、higher usage of mechanical ventilation, However There is no statistically significant (P＞0.05). There were significant differences in drug resistance between multiple antibiotics and strains. Conclusion: The ICU of our hospital has been established for a short time, the infection rate of Acinetobacter baumannii is high, the isolation rate shows a downward trend, the drug resistance rate increases year by year, and the effective treatment drugs are few. The use of multiple antibiotics and strain resistance are risk factors for the death of Acinetobacter baumannii infected patients. In order to reduce the infection and transmission of Acinetobacter baumannii, we should strengthen the concept of infection control, interrupt the transmission of Acinetobacter baumannii and strengthen the clinical management of antibiotics.
|
|
|
|
|
|
[1] Nicholas S, Britt PharmD, MS, David J Ritchie Pharm D, et, al.Clinical epidemiology of carbapenem resistant gram-negative sepsis among hospitalized patients: shifting burden of disease[J].American Journal of Infection Control, 2018, 4(18):30180~30189.
[2] 尚红,王毓三,申子瑜.全国临床检验操作规范[M].第3版.北京:人民卫生出版社,2014.720~721.
[3] Clinical and laboratory standards institute.Performance standards for antimicrobial susceptibility testing:twenty-fifth informational supplement:M100-S25[M].2015.1~30.
[4] 卫生部.医院感染诊断标准:试行[M].2001.1~2.
[5] 陈佰义,何礼贤,胡必杰.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76~85.
[6] 胡付品,郭燕,朱德妹,等.2016年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2017,17(7):481~491.
[7] 刘秋萍,徐凌.耐药鲍曼不动杆菌药物治疗的研究进展[J].实用药物与临床,2018,21(2):212~217.
[8] 王国恩,马琪,刘敏龙,等.ICU病房鲍曼不动杆菌感染状况及耐药性分析[J].中国医药导报,2015,12(27):153~155.
[9] Munoz-Price LS, Arheart K, Nordmann P, et, al.Eighteen years of experience with acinetobacter baumannii in a tertiary care hospital[J].Critical Care Medicine, 2013, 42(12):2733~2742. |
|
|
|
2019, Vol. 25 
